Top

Published in:

01-12-2010 | NON-THEMATIC REVIEW

Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis

Authors: Ming Shi, Dan Liu, Huijun Duan, Beifen Shen, Ning Guo

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Abstract

Breast cancer is the most common malignancy with the highest incidence among women in the world. Metastasis is the major reason for breast cancer-related deaths. The precise molecular circuitry that governs the metastasis process has not been completely understood. Discoveries of microRNAs (miRNAs) open a new avenue for cancer metastasis research. It has become clear that alterations of miRNA expression contribute to cancer pathogenesis. miRNAs control a wide array of physiological and pathological processes, including development, differentiation, cellular proliferation, programmed cell death, oncogenesis, and metastasis by modulating the expression of their cognate target genes through cleaving mRNA molecules or inhibiting their translation. Some miRNAs are associated with the invasive and metastatic phenotype of breast cancer cell lines or identified in metastatic tumor tissues and lymph nodes. Some miRNAs serve as metastasis suppressors and their expression is frequently downregulated or lost in both breast cancer cell lines and metastatic foci. Some miRNAs are considered to play key roles in the phenotype formation of breast cancer stem cells. This review will focus on recent discoveries related to the miRNAs involved in the metastasis of breast cancer and discuss the implications for the diagnosis, prognosis, and therapeutic strategies of breast cancer.

Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60(5), 277–300.

Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nature Reviews. Genetics, 9(2), 102–114.PubMed

Tavazoie, S. F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175), 147–152.PubMed

Israel, A., Sharan, R., Ruppin, E., & Galun, E. (2009). Increased microRNA activity in human cancers. PLoS ONE, 4(6), e6045.PubMed

Dumont, N., & Tlsty, T. D. (2009). Reflections on miR-ing effects in metastasis. Cancer Cell, 16(1), 3–4.PubMed

Hurst, D. R., Edmonds, M. D., & Welch, D. R. (2009). Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Research, 69(19), 7495–7498.PubMed

Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 101(9), 2999–3004.PubMed

Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., et al. (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 103(24), 9136–9141.PubMed

Sempere, L. F., Christensen, M., Silahtaroglu, A., Bak, M., Heath, C. V., Schwartz, G., et al. (2007). Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Research, 67(24), 11612–11620.PubMed

10.

Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.PubMed

11.

Yan, L. X., Huang, X. F., Shao, Q., Huang, M. Y., Deng, L., Wu, Q. L., et al. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14(11), 2348–2360.PubMed

12.

Fassan, M., Baffa, R., Palazzo, J. P., Lloyd, J., Crosariol, M., Liu, C. G., et al. (2009). MicroRNA expression profiling of male breast cancer. Breast Cancer Research, 11(4), R58.PubMed

13.

Lehmann, U., Streichert, T., Otto, B., Albat, C., Hasemeier, B., Christgen, H., et al. (2010). Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer, 10, 109.PubMed

14.

Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S. F., Dunning, M. J., et al. (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology, 8(10), R214.PubMed

15.

Van ’T Veer, L. J., Dai, H., Van De Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415(6871), 530–536.PubMed

16.

Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., et al. (2006). Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute, 98(4), 262–272.PubMed

17.

Yu, K., Lee, C. H., Tan, P. H., Hong, G. S., Wee, S. B., Wong, C. Y., et al. (2004). A molecular signature of the Nottingham prognostic index in breast cancer. Cancer Research, 64(9), 2962–2968.PubMed

18.

Yu, J. X., Sieuwerts, A. M., Zhang, Y., Martens, J. W., Smid, M., Klijn, J. G., et al. (2007). Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer, 7, 182.PubMed

19.

Baffa, R., Fassan, M., Volinia, S., O’hara, B., Liu, C. G., Palazzo, J. P., et al. (2009). MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. The Journal of Pathology, 219(2), 214–221.PubMed

20.

Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., et al. (2010). MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine, 16(8), 909–914.PubMed

21.

Qian, B., Katsaros, D., Lu, L., Preti, M., Durando, A., Arisio, R., et al. (2009). High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Research and Treatment, 117(1), 131–140.PubMed

22.

Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y. Y. (2008). MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Research, 18(3), 350–359.PubMed

23.

Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., et al. (2010). MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. Journal of Experimental & Clinical Cancer Research, 29, 29.

24.

Huang, T. H., Wu, F., Loeb, G. B., Hsu, R., Heidersbach, A., Brincat, A., et al. (2009). Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. The Journal of Biological Chemistry, 284(27), 18515–18524.PubMed

25.

Huang, G. L., Zhang, X. H., Guo, G. L., Huang, K. T., Yang, K. Y., Shen, X., et al. (2009). Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncology Reports, 21(3), 673–679.PubMed

26.

Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682–688.PubMed

27.

Carrio, M., Arderiu, G., Myers, C., & Boudreau, N. J. (2005). Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Research, 65(16), 7177–7185.PubMed

28.

Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., et al. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnology, 28(4), 341–347.PubMed

29.

Moriarty, C. H., Pursell, B., & Mercurio, A. M. (2010). miR-10b targets Tiam1: Implications for Rac activation and carcinoma migration. The Journal of Biological Chemistry, 285(27), 20541–20546.PubMed

30.

Gee, H. E., Camps, C., Buffa, F. M., Colella, S., Sheldon, H., & Gleadle, J. M. (2008). MicroRNA-10b and breast cancer metastasis. Nature, 455(7216), E8–E9. author reply E9.PubMed

31.

Voorhoeve, P. M., Le Sage, C., Schrier, M., Gillis, A. J., Stoop, H., Nagel, R., et al. (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell, 124(6), 1169–1181.PubMed

32.

Huang, Q., Gumireddy, K., Schrier, M., Le Sage, C., Nagel, R., Nair, S., et al. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology, 10(2), 202–210.PubMed

33.

Crosby, M. E., Devlin, C. M., Glazer, P. M., Calin, G. A., & Ivan, M. (2009). Emerging roles of microRNAs in the molecular responses to hypoxia. Current Pharmaceutical Design, 15(33), 3861–3866.PubMed

34.

Crosby, M. E., Kulshreshtha, R., Ivan, M., & Glazer, P. M. (2009). MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Research, 69(3), 1221–1229.PubMed

35.

Batty, D., Rapic’-Otrin, V., Levine, A. S., & Wood, R. D. (2000). Stable binding of human XPC complex to irradiated DNA confers strong discrimination for damaged sites. Journal of Molecular Biology, 300(2), 275–290.PubMed

36.

Thiery, J. P., Acloque, H., Huang, R. Y., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell, 139(5), 871–890.PubMed

37.

Voulgari, A., & Pintzas, A. (2009). Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochimica et Biophysica Acta, 1796(2), 75–90.PubMed

38.

Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biology, 12(3), 247–256.PubMed

39.

Sun, Y., Wu, J., Wu, S. H., Thakur, A., Bollig, A., Huang, Y., et al. (2009). Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Research and Treatment, 118(1), 185–196.PubMed

40.

Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., et al. (2010). A MicroRNA targeting dicer for metastasis control. Cell, 141(7), 1195–1207.PubMed

41.

Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136(2), 215–233.PubMed

42.

Grelier, G., Voirin, N., Ay, A. S., Cox, D. G., Chabaud, S., Treilleux, I., et al. (2009). Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype. British Journal of Cancer, 101(4), 673–683.PubMed

43.

Merritt, W. M., Lin, Y. G., Han, L. Y., Kamat, A. A., Spannuth, W. A., Schmandt, R., et al. (2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. The New England Journal of Medicine, 359(25), 2641–2650.PubMed

44.

Kumar, M. S., Pester, R. E., Chen, C. Y., Lane, K., Chin, C., Lu, J., et al. (2009). Dicer1 functions as a haploinsufficient tumor suppressor. Genes & Development, 23(23), 2700–2704.

45.

Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838.PubMed

46.

Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., & Jacks, T. (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics, 39(5), 673–677.PubMed

47.

Inui, M., Martello, G., & Piccolo, S. (2010). MicroRNA control of signal transduction. Nature Reviews. Molecular Cell Biology, 11(4), 252–263.PubMed

48.

Hoser, M., Baader, S. L., Bosl, M. R., Ihmer, A., Wegner, M., & Sock, E. (2007). Prolonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia. The Journal of Neuroscience, 27(20), 5495–5505.PubMed

49.

Scharer, C. D., Mccabe, C. D., Ali-Seyed, M., Berger, M. F., Bulyk, M. L., & Moreno, C. S. (2009). Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Research, 69(2), 709–717.PubMed

50.

Orend, G., & Chiquet-Ehrismann, R. (2006). Tenascin-C induced signaling in cancer. Cancer Letters, 244(2), 143–163.PubMed

51.

Liu, B., Peng, X. C., Zheng, X. L., Wang, J., & Qin, Y. W. (2009). MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer, 66(2), 169–175.PubMed

52.

Crawford, M., Brawner, E., Batte, K., Yu, L., Hunter, M. G., Otterson, G. A., et al. (2008). MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochemical and Biophysical Research Communications, 373(4), 607–612.PubMed

53.

Feng, R., Chen, X., Yu, Y., Su, L., Yu, B., Li, J., et al. (2010). miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Letters, 298(1), 50–63.PubMed

54.

Li, X., Shen, Y., Ichikawa, H., Antes, T., & Goldberg, G. S. (2009). Regulation of miRNA expression by Src and contact normalization: Effects on nonanchored cell growth and migration. Oncogene, 28(48), 4272–4283.PubMed

55.

Feller, S. M. (2001). Crk family adaptors-signalling complex formation and biological roles. Oncogene, 20(44), 6348–6371.PubMed

56.

Calvo, A., Catena, R., Noble, M. S., Carbott, D., Gil-Bazo, I., Gonzalez-Moreno, O., et al. (2008). Identification of VEGF-regulated genes associated with increased lung metastatic potential: Functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene, 27(40), 5373–5384.PubMed

57.

Cueni, L. N., Hegyi, I., Shin, J. W., Albinger-Hegyi, A., Gruber, S., Kunstfeld, R., et al. (2010). Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. The American Journal of Pathology, 177(2), 1004–1016.PubMed

58.

Naugler, W. E., & Karin, M. (2008). NF-kappaB and cancer-identifying targets and mechanisms. Current Opinion in Genetics & Development, 18(1), 19–26.

59.

Coppe, J. P., Kauser, K., Campisi, J., & Beausejour, C. M. (2006). Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. The Journal of Biological Chemistry, 281(40), 29568–29574.PubMed

60.

Bhaumik, D., Scott, G. K., Schokrpur, S., Patil, C. K., Campisi, J., & Benz, C. C. (2008). Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27(42), 5643–5647.PubMed

61.

Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Research, 69(4), 1279–1283.PubMed

62.

Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szasz, A. M., Wang, Z. C., et al. (2009). A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137(6), 1032–1046.PubMed

63.

Lee, E. J., Baek, M., Gusev, Y., Brackett, D. J., Nuovo, G. J., & Schmittgen, T. D. (2008). Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA, 14(1), 35–42.PubMed

64.

Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., et al. (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Molecular Biology of the Cell, 12(1), 27–36.PubMed

65.

Shi, B., Sepp-Lorenzino, L., Prisco, M., Linsley, P., Deangelis, T., & Baserga, R. (2007). Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. The Journal of Biological Chemistry, 282(45), 32582–32590.PubMed

66.

Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., et al. (2009). p53 represses c-Myc through induction of the tumor suppressor miR-145. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3207–3212.PubMed

67.

Schepeler, T., Reinert, J. T., Ostenfeld, M. S., Christensen, L. L., Silahtaroglu, A. N., Dyrskjot, L., et al. (2008). Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Research, 68(15), 6416–6424.PubMed

68.

Kufe, D. W. (2009). Mucins in cancer: Function, prognosis and therapy. Nature Reviews. Cancer, 9(12), 874–885.PubMed

69.

Sachdeva, M., & Mo, Y. Y. (2010). MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Research, 70(1), 378–387.PubMed

70.

Shan, S. W., Lee, D. Y., Deng, Z., Shatseva, T., Jeyapalan, Z., Du, W. W., et al. (2009). MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nature Cell Biology, 11(8), 1031–1038.PubMed

71.

Yu, Z., Willmarth, N. E., Zhou, J., Katiyar, S., Wang, M., Liu, Y., et al. (2010). microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proceedings of the National Academy of Sciences of the United States of America, 107(18), 8231–8236.PubMed

72.

Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M. C., Liu, M., et al. (2008). A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. The Journal of Cell Biology, 182(3), 509–517.PubMed

73.

O’donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435(7043), 839–843.PubMed

74.

Li, X., & Carthew, R. W. (2005). A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell, 123(7), 1267–1277.PubMed

75.

Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., et al. (2008). microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Research, 68(10), 3566–3572.PubMed

76.

Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., & Leedman, P. J. (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. The Journal of Biological Chemistry, 284(9), 5731–5741.PubMed

77.

Reddy, S. D., Ohshiro, K., Rayala, S. K., & Kumar, R. (2008). MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Research, 68(20), 8195–8200.PubMed

78.

Reddy, S. D., Pakala, S. B., Ohshiro, K., Rayala, S. K., & Kumar, R. (2009). MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Research, 69(14), 5639–5642.PubMed

79.

Manavathi, B., & Kumar, R. (2007). Metastasis tumor antigens, an emerging family of multifaceted master coregulators. The Journal of Biological Chemistry, 282(3), 1529–1533.PubMed

80.

Lim, L. P., Glasner, M. E., Yekta, S., Burge, C. B., & Bartel, D. P. (2003). Vertebrate microRNA genes. Science, 299(5612), 1540.PubMed

81.

Wienholds, E., Kloosterman, W. P., Miska, E., Alvarez-Saavedra, E., Berezikov, E., De Bruijn, E., et al. (2005). MicroRNA expression in zebrafish embryonic development. Science, 309(5732), 310–311.PubMed

82.

Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129(7), 1401–1414.PubMed

83.

Wu, H., & Mo, Y. Y. (2009). Targeting miR-205 in breast cancer. Expert Opinion on Therapeutic Targets, 13(12), 1439–1448.PubMed

84.

Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601.PubMed

85.

Wu, H., Zhu, S., & Mo, Y. Y. (2009). Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Research, 19(4), 439–448.PubMed

86.

Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nature Reviews. Cancer, 9(7), 463–475.PubMed

87.

Xue, C., Liang, F., Mahmood, R., Vuolo, M., Wyckoff, J., Qian, H., et al. (2006). ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Research, 66(3), 1418–1426.PubMed

88.

Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T., et al. (2009). microRNA-205 regulates HER3 in human breast cancer. Cancer Research, 69(6), 2195–2200.PubMed

89.

Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports, 9(6), 582–589.PubMed

90.

Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. The Journal of Biological Chemistry, 283(22), 14910–14914.PubMed

91.

Olson, P., Lu, J., Zhang, H., Shai, A., Chun, M. G., Wang, Y., et al. (2009). MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes & Development, 23(18), 2152–2165.

92.

Park, S. M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes & Development, 22(7), 894–907.

93.

Gibbons, D. L., Lin, W., Creighton, C. J., Rizvi, Z. H., Gregory, P. A., Goodall, G. J., et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes & Development, 23(18), 2140–2151.

94.

Hurteau, G. J., Carlson, J. A., Spivack, S. D., & Brock, G. J. (2007). Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Research, 67(17), 7972–7976.PubMed

95.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983–3988.PubMed

96.

Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nature Reviews. Cancer, 8(10), 755–768.PubMed

97.

Pece, S., Tosoni, D., Confalonieri, S., Mazzarol, G., Vecchi, M., Ronzoni, S., et al. (2010). Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 140(1), 62–73.PubMed

98.

Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., et al. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell, 138(6), 1083–1095.PubMed

99.

Diallo, R., Schaefer, K. L., Poremba, C., Shivazi, N., Willmann, V., Buerger, H., et al. (2001). Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. The Journal of Pathology, 193(1), 27–32.PubMed

100.

Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J., et al. (2003). In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes & Development, 17(10), 1253–1270.

101.

Al-Hajj, M. (2007). Cancer stem cells and oncology therapeutics. Current Opinion in Oncology, 19(1), 61–64.PubMed

102.

Yu, F., Yao, H., Zhu, P., Zhang, X., Pan, Q., Gong, C., et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6), 1109–1123.PubMed

103.

Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nature Cell Biology, 11(12), 1487–1495.PubMed

104.

Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., Qian, D., et al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 138(3), 592–603.PubMed

105.

Yu, F., Deng, H., Yao, H., Liu, Q., Su, F., & Song, E. (2010). Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene, 29(29), 4194–4204.PubMed

106.

Park, I. K., Qian, D., Kiel, M., Becker, M. W., Pihalja, M., Weissman, I. L., et al. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature, 423(6937), 302–305.PubMed

107.

Lessard, J., & Sauvageau, G. (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature, 423(6937), 255–260.PubMed

108.

Akala, O. O., Park, I. K., Qian, D., Pihalja, M., Becker, M. W., & Clarke, M. F. (2008). Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors. Nature, 453(7192), 228–232.PubMed

109.

Bracken, A. P., & Helin, K. (2009). Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nature Reviews. Cancer, 9(11), 773–784.PubMed

110.

Roush, S., & Slack, F. J. (2008). The let-7 family of microRNAs. Trends in Cell Biology, 18(10), 505–516.PubMed

111.

Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647.PubMed

112.

Viswanathan, S. R., Powers, J. T., Einhorn, W., Hoshida, Y., Ng, T. L., Toffanin, S., et al. (2009). Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics, 41(7), 843–848.PubMed

113.

Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews. Cancer, 6(4), 259–269.PubMed

114.

Dangi-Garimella, S., Yun, J., Eves, E. M., Newman, M., Erkeland, S. J., Hammond, S. M., et al. (2009). Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. The EMBO Journal, 28(4), 347–358.PubMed

115.

Mayr, C., Hemann, M. T., & Bartel, D. P. (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315(5818), 1576–1579.PubMed

116.

Chang, T. C., Zeitels, L. R., Hwang, H. W., Chivukula, R. R., Wentzel, E. A., Dews, M., et al. (2009). Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3384–3389.PubMed

117.

Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009). An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell, 139(4), 693–706.PubMed

118.

Cabodi, S., & Taverna, D. (2010). Interfering with inflammation: A new strategy to block breast cancer self-renewal and progression? Breast Cancer Research, 12(2), 305.PubMed

119.

Heo, I., Joo, C., Cho, J., Ha, M., Han, J., & Kim, V. N. (2008). Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Molecular Cell, 32(2), 276–284.PubMed

120.

Rybak, A., Fuchs, H., Smirnova, L., Brandt, C., Pohl, E. E., Nitsch, R., et al. (2008). A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nature Cell Biology, 10(8), 987–993.PubMed

121.

Viswanathan, S. R., Daley, G. Q., & Gregory, R. I. (2008). Selective blockade of microRNA processing by Lin28. Science, 320(5872), 97–100.PubMed

122.

Heo, I., Joo, C., Kim, Y. K., Ha, M., Yoon, M. J., Cho, J., et al. (2009). TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell, 138(4), 696–708.PubMed

123.

Hagan, J. P., Piskounova, E., & Gregory, R. I. (2009). Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nature Structural & Molecular Biology, 16(10), 1021–1025.

124.

Dalerba, P., & Clarke, M. F. (2007). Cancer stem cells and tumor metastasis: First steps into uncharted territory. Cell Stem Cell, 1(3), 241–242.PubMed

125.

Wu, F., Zhu, S., Ding, Y., Beck, W. T., & Mo, Y. Y. (2009). MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clinical Cancer Research, 15(5), 1550–1557.PubMed

126.

Muller, D. W., & Bosserhoff, A. K. (2008). Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene, 27(52), 6698–6706.PubMed

127.

Yu, Z., Baserga, R., Chen, L., Wang, C., Lisanti, M. P., & Pestell, R. G. (2010). microRNA, cell cycle, and human breast cancer. The American Journal of Pathology, 176(3), 1058–1064.PubMed

128.

Brennecke, J., Stark, A., Russell, R. B., & Cohen, S. M. (2005). Principles of microRNA-target recognition. PLoS Biology, 3(3), e85.PubMed

129.

Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., et al. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer, 5, 24.PubMed

130.

Lowery, A. J., Miller, N., Devaney, A., Mcneill, R. E., Davoren, P. A., Lemetre, C., et al. (2009). MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Research, 11(3), R27.PubMed

131.

Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., et al. (2010). MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. The Journal of Biological Chemistry, 285(28), 21496–21507.PubMed

132.

Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251(3), 499–505.PubMed

Title: Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis
Authors: Ming Shi
Dan Liu
Huijun Duan
Beifen Shen
Ning Guo
Publication date: 01-12-2010
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9265-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Feedback regulation of proteasome gene expression and its implications in cancer therapy

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

DNA repair pathways and their implication in cancer treatment

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC)

Perspectives on the mesenchymal origin of metastatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer